STING1 and neoplasm: Notably, although the impact of STING agonists on the activation of IDO in the immune system or tumor microenvironment has not yet been evaluated, this potential effect on IDO activation must be investigated before applying STING agonists to treat cancer, whereas combined using IDO inhibitors may enhance the immunotherapeutic effect of STING agonists.